home / stock / avte / avte articles
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial h...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply du...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused...
News, Short Squeeze, Breakout and More Instantly...
Aerovate Therapeutics Inc. Company Name:
AVTE Stock Symbol:
NASDAQ Market:
Aerovate Therapeutics Inc. Website:
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 476.9% to $0.75 on volume of 1,104,730,765 shares NVIDIA Corporation (NVDA) fell 0.7% to $130.98 on volume of 283,604,651 shares ENDRA Life Sciences Inc. (NDRA) rose 34.2% to $0.139 on volume of 219,783,92...